SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis

Reuters

Jul 14

SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis

SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2551902500"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551902500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551902500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551902500","market":"us","top_or_hot":-1,"title":"SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-14 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03681","symbol_name":"中国抗体-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL9hp38S:1","article_id":"2551902500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551902500","pubTimestamp":1752487544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 , for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03681":"中国抗体-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"SinoMab BioScience Ltd.宣布正在对SM03（Suciraslimab）治疗类风湿性关节炎进行监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":0.9},"content_text":"SinoMab BioScience Ltd. Announces Ongoing Regulatory Review for SM03 (Suciraslimab) in Treatment of Rheumatoid Arthritis\n    \n\n        SinoMab BioScience Ltd. has announced an update on the ongoing regulatory review of its flagship product, SM03 (Suciraslimab), for the treatment of rheumatoid arthritis. The company has made significant progress, having already met the primary endpoint in a Phase III clinical study in China. Suciraslimab, known for its unique mechanism of action, targets and inhibits autoreactive B cells, offering promise for long-term efficacy and safety in autoimmune disease treatment. SinoMab is also planning a new clinical development program for Suciraslimab to treat systemic lupus erythematosus. The company continues to advance its diverse pipeline, including further clinical study of SM17, whose Phase 1b clinical trial results were recently published.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}